Subha Perni1, Abdallah S R Mohamed2, Jacob Scott3, Heiko Enderling4, Adam S Garden5, G Brandon Gunn5, David I Rosenthal5, Clifton D Fuller6. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA; Columbia University College of Physicians & Surgeons, 630 West 168th Street, New York, NY, USA. Electronic address: sp3128@columbia.edu. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Chamblion Street, El Azareeta, Alexandria, Egypt. Electronic address: ASMohamed@mdanderson.org. 3. Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA. Electronic address: scottj10@ccf.org. 4. Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA. Electronic address: Heiko.Enderling@moffitt.org. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA. 6. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA. Electronic address: cdfuller@mdanderson.org.
Abstract
OBJECTIVES: Volumetric tumor growth velocity (TGV) reflects in vitro tumor aggressiveness, but its prognostic value has not been investigated in vivo. We examined the prognostic impact of TGV on oncologic outcomes in patients with oropharyngeal squamous cell cancer (OSCC). MATERIALS AND METHODS: 101 OSCC patients with two pretreatment CTs with time gap of 2 or more weeks treated at a single institution between 2004 and 2008 were identified. Primary tumor and nodal targets were segmented in scans. Linear growth rates were calculated. Recursive partitioning analysis (RPA) identified cut point associated with outcomes. RESULTS: Median follow-up was 59months (range 7-118). Median primary TGV was 0.65% increase per day (range 0-9.37%). RPA identified TGV cut point associated with local control (LC) of 1% per day. Patients with higher TGV had decreased 5-year LC (73% vs. 98%, p=0.0004), distant control (DC, 62% vs. 91%, p=0.0007), and overall survival (OS, 38% versus 93%, p<0.0001). In multivariate analysis including demographics, tumor stage, subsite, and treatment factors, TGV⩾1% per day independently predicted worsened LC (p = 0.02), DC (p = 0.003), and OS (p < 0.0001). However, this TGV cutoff was not significantly predictive of LC, DC, or OS for a subset of presumed HPV-positive patients. CONCLUSION: OSCC TGV⩾1% per day is a substantive negative prognostic indicator for disease control and overall survival, particularly in HPV non-associated tumors. This novel CT-based volumetric assessment of TGV suggests a simple methodology for risk stratification of patients.
OBJECTIVES: Volumetric tumor growth velocity (TGV) reflects in vitro tumor aggressiveness, but its prognostic value has not been investigated in vivo. We examined the prognostic impact of TGV on oncologic outcomes in patients with oropharyngeal squamous cell cancer (OSCC). MATERIALS AND METHODS: 101 OSCC patients with two pretreatment CTs with time gap of 2 or more weeks treated at a single institution between 2004 and 2008 were identified. Primary tumor and nodal targets were segmented in scans. Linear growth rates were calculated. Recursive partitioning analysis (RPA) identified cut point associated with outcomes. RESULTS: Median follow-up was 59months (range 7-118). Median primary TGV was 0.65% increase per day (range 0-9.37%). RPA identified TGV cut point associated with local control (LC) of 1% per day. Patients with higher TGV had decreased 5-year LC (73% vs. 98%, p=0.0004), distant control (DC, 62% vs. 91%, p=0.0007), and overall survival (OS, 38% versus 93%, p<0.0001). In multivariate analysis including demographics, tumor stage, subsite, and treatment factors, TGV⩾1% per day independently predicted worsened LC (p = 0.02), DC (p = 0.003), and OS (p < 0.0001). However, this TGV cutoff was not significantly predictive of LC, DC, or OS for a subset of presumed HPV-positive patients. CONCLUSION: OSCC TGV⩾1% per day is a substantive negative prognostic indicator for disease control and overall survival, particularly in HPV non-associated tumors. This novel CT-based volumetric assessment of TGV suggests a simple methodology for risk stratification of patients.
Authors: S Bisdas; Z Rumboldt; J Wagenblast; M Baghi; T S Koh; M Hambek; T J Vogl; M G Mack Journal: AJNR Am J Neuroradiol Date: 2009-04 Impact factor: 3.825
Authors: Carryn M Anderson; Wenqing Sun; John M Buatti; Joan E Maley; Bruno Policeni; Sarah L Mott; John E Bayouth Journal: Jacobs J Radiat Oncol Date: 2014-09
Authors: Stephen L Breen; Julia Publicover; Shiroma De Silva; Greg Pond; Kristy Brock; Brian O'Sullivan; Bernard Cummings; Laura Dawson; Anne Keller; John Kim; Jolie Ringash; Eugene Yu; Aaron Hendler; John Waldron Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-26 Impact factor: 7.038
Authors: R Hermans; K Op de beeck; W Van den Bogaert; A Rijnders; L Staelens; M Feron; E Bellon Journal: Int J Radiat Oncol Biol Phys Date: 2001-05-01 Impact factor: 7.038
Authors: Remy Lim; Anne Eaton; Nancy Y Lee; Jeremy Setton; Nisha Ohri; Shyam Rao; Richard Wong; Matthew Fury; Heiko Schöder Journal: J Nucl Med Date: 2012-08-14 Impact factor: 10.057
Authors: Joana Caldas-Magalhaes; Nina Kooij; Hans Ligtenberg; Elise A Jager; Tim Schakel; Nicolien Kasperts; Frank A Pameijer; Chris H J Terhaard; Luuk M Janssen; Paul J van Diest; Marielle E P Philippens; Cornelis P J Raaijmakers Journal: Acta Oncol Date: 2015-03-03 Impact factor: 4.089
Authors: Elizabeth H Dibble; Ana C Lara Alvarez; Minh-Tam Truong; Gustavo Mercier; Earl F Cook; Rathan M Subramaniam Journal: J Nucl Med Date: 2012-04-09 Impact factor: 10.057
Authors: Mark J Been; Joanna Watkins; Ryan M Manz; Lindell R Gentry; Glen E Leverson; Paul M Harari; Gregory K Hartig Journal: Laryngoscope Date: 2008-08 Impact factor: 3.325
Authors: Linda G W Kerkmeijer; Clifton D Fuller; Helena M Verkooijen; Marcel Verheij; Ananya Choudhury; Kevin J Harrington; Chris Schultz; Arjun Sahgal; Steven J Frank; Joel Goldwein; Kevin J Brown; Bruce D Minsky; Marco van Vulpen Journal: Front Oncol Date: 2016-10-13 Impact factor: 6.244